# Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5

> **NCT00652002** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 450 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** budesonide/formoterol
- **DRUG:** budesonide
- **DRUG:** formoterol

## Key facts

- **NCT ID:** NCT00652002
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** —
- **Final completion:** 2004-01
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00652002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00652002, "Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00652002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*